{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:34:03Z","timestamp":1776875643219,"version":"3.51.2"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,9,4]],"date-time":"2010-09-04T00:00:00Z","timestamp":1283558400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00213-010-2002-9","type":"journal-article","created":{"date-parts":[[2010,9,3]],"date-time":"2010-09-03T10:15:02Z","timestamp":1283508902000},"page":"1-9","source":"Crossref","is-referenced-by-count":6,"title":["Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine"],"prefix":"10.1007","volume":"213","author":[{"given":"Hakuei","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Yoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriomi","family":"Kuroki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Odagaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsushi","family":"Kazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Toyoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taeko","family":"Maruki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,4]]},"reference":[{"key":"2002_CR1","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-IV)","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders (DSM-IV), 4th edn. American Psychiatric Association Publications Division, Washington DC","edition":"4"},{"key":"2002_CR2","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.metabol.2006.04.013","volume":"55","author":"RA Benndorf","year":"2006","unstructured":"Benndorf RA, Rudolph T, Appel D, Schwedhelm E, Maas R, Schulze F, Silberhorn E, B\u00f6ger RH (2006) Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 55:1159\u20131164","journal-title":"Metabolism"},{"key":"2002_CR3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","volume":"37","author":"JT Callaghan","year":"1999","unstructured":"Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM (1999) Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37:177\u2013193","journal-title":"Clin Pharmacokinet"},{"key":"2002_CR4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4088\/JCP.v67n0408","volume":"67","author":"CU Correll","year":"2006","unstructured":"Correll CU, Frederickson AM, Kane JM, Manu P (2006) Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 67:575\u2013583","journal-title":"J Clin Psychiatry"},{"key":"2002_CR5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archinte.161.11.1413","volume":"161","author":"Y Cui","year":"2001","unstructured":"Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL (2001) Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 161:1413\u20131419","journal-title":"Arch Intern Med"},{"key":"2002_CR6","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.eurpsy.2005.05.011","volume":"21","author":"M Hert De","year":"2006","unstructured":"De Hert M, Van Eyck D, Hanssens L, Peuskens H, Thys E, Wampers M, Scheen A, Peuskens J (2006) Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics? Eur Psychiatry 21:224\u2013226","journal-title":"Eur Psychiatry"},{"key":"2002_CR7","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S0090-9556(24)15038-6","volume":"27","author":"T Ebner","year":"1999","unstructured":"Ebner T, Heinzel G, Prox A, Beschke K, Wachsmuth H (1999) Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab Dispos 27:1143\u20131149","journal-title":"Drug Metab Dispos"},{"key":"2002_CR8","unstructured":"Eli Lilly Japan KK (2010) Zyprexa\u00ae package insert, 14th edn. revised March, 2010 (in Japanese)"},{"key":"2002_CR9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1291\/hypres.28.209","volume":"28","author":"R Fogari","year":"2005","unstructured":"Fogari R, Derosa G, Zoppi A, Rinaldi A, Lazzari P, Fogari E, Mugellini A, Preti P (2005) Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 28:209\u2013214","journal-title":"Hypertens Res"},{"issue":"Suppl 1","key":"2002_CR10","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.diabres.2003.11.024","volume":"66","author":"M Fukushima","year":"2004","unstructured":"Fukushima M, Suzuki H, Seino Y (2004) Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 66(Suppl 1):S37\u2013S43","journal-title":"Diabetes Res Clin Pract"},{"key":"2002_CR11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.euroneuro.2006.09.005","volume":"17","author":"JM Haro","year":"2007","unstructured":"Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D, SOHO Study Group (2007) Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 17:235\u2013244","journal-title":"Eur Neuropsychopharmacol"},{"key":"2002_CR12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.62.1.19","volume":"62","author":"DC Henderson","year":"2005","unstructured":"Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC (2005) Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62:19\u201328","journal-title":"Arch Gen Psychiatry"},{"key":"2002_CR13","unstructured":"Japan Diabetes Society (2007) Treatment guide for diabetes 2007. Bunkodo Co., Ltd. Tokyo, Japan"},{"key":"2002_CR14","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE trial group (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022\u20132031","journal-title":"Lancet"},{"key":"2002_CR15","volume-title":"The positive and negative syndrome scale (PANSS) manual","author":"SR Kay","year":"1986","unstructured":"Kay SR, Opler LA, Fizbein A (1986) The positive and negative syndrome scale (PANSS) manual. Multi-Health System, North Tonawanda"},{"key":"2002_CR16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4088\/JCP.v62n0204","volume":"62","author":"BJ Kinon","year":"2001","unstructured":"Kinon BJ, Basson BR, Gilmore JA, Tollefson GD (2001) Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62:92\u2013100","journal-title":"J Clin Psychiatry"},{"key":"2002_CR17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1592\/phco.22.11.841.33629","volume":"22","author":"EA Koller","year":"2002","unstructured":"Koller EA, Doraiswamy PM (2002) Olanzapine-associated diabetes mellitus. Pharmacotherapy 22:841\u2013852","journal-title":"Pharmacotherapy"},{"key":"2002_CR18","first-page":"21","volume":"47","author":"SM Kyvelou","year":"2006","unstructured":"Kyvelou SM, Vyssoulis GP, Karpanou EA, Adamopoulos DN, Zervoudaki AI, Pietri PG, Stefanadis CI (2006) Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol 47:21\u201328","journal-title":"Hellenic J Cardiol"},{"key":"2002_CR19","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/oxfordjournals.aje.a116768","volume":"137","author":"M Laakso","year":"1993","unstructured":"Laakso M (1993) How good a marker is insulin level for insulin resistance? Am J Epidemiol 137:959\u2013965","journal-title":"Am J Epidemiol"},{"key":"2002_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31\u201341","journal-title":"Lancet"},{"key":"2002_CR21","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209\u20131223","journal-title":"N Engl J Med"},{"key":"2002_CR22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/oxfordjournals.epirev.a017978","volume":"20","author":"AD Liese","year":"1998","unstructured":"Liese AD, Mayer-Davis EJ, Haffner SM (1998) Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev 20:157\u2013172","journal-title":"Epidemiol Rev"},{"key":"2002_CR23","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/npp.2010.21","volume":"35","author":"L Maayan","year":"2010","unstructured":"Maayan L, Vakhrusheva J, Correll CU (2010) Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 35:1520\u20131530","journal-title":"Neuropsychopharmacology"},{"key":"2002_CR24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1291\/hypres.31.657","volume":"31","author":"H Makino","year":"2008","unstructured":"Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S, INNOVATION Study Group (2008) Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. Hypertens Res 31:657\u2013664","journal-title":"Hypertens Res"},{"key":"2002_CR25","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","volume":"25","author":"G Mancia","year":"2007","unstructured":"Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O\u2019Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B, Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology (2007) Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens 25:1105\u20131187","journal-title":"J Hypertens"},{"key":"2002_CR26","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","volume":"22","author":"M Matsuda","year":"1999","unstructured":"Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diab Care 22:1462\u20131470","journal-title":"Diab Care"},{"key":"2002_CR27","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412\u2013419","journal-title":"Diabetologia"},{"key":"2002_CR28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-003-1529-4","volume":"170","author":"KI Melkersson","year":"2003","unstructured":"Melkersson KI, Dahl ML (2003) Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 170:157\u2013166","journal-title":"Psychopharmacology (Berl)"},{"key":"2002_CR29","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0140-6736(07)60669-2","volume":"28","author":"S Mochizuki","year":"2007","unstructured":"Mochizuki S, Dahl\u00f6f B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N, Jikei Heart Study group (2007) Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 28:1431\u20131439","journal-title":"Lancet"},{"key":"2002_CR30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s002280050317","volume":"52","author":"P M\u00fcller","year":"1997","unstructured":"M\u00fcller P, Flesch G, de Gasparo M, Gasparini M, Howald H (1997) Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol 52:441\u2013449","journal-title":"Eur J Clin Pharmacol"},{"key":"2002_CR31","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.metabol.2006.04.011","volume":"55","author":"JM Nagel","year":"2006","unstructured":"Nagel JM, Tietz AB, G\u00f6ke B, Parhofer KG (2006) The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism 55:1149\u20131154","journal-title":"Metabolism"},{"key":"2002_CR32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/00498250500158175","volume":"35","author":"A Nakashima","year":"2005","unstructured":"Nakashima A, Kawashita H, Masuda N, Saxer C, Niina M, Nagae Y, Iwasaki K (2005) Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes. Xenobiotica 35:589\u2013602","journal-title":"Xenobiotica"},{"issue":"Suppl 7","key":"2002_CR33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1017\/S1092852900026663","volume":"11","author":"HA Nasrallah","year":"2006","unstructured":"Nasrallah HA (2006) Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectr 11(Suppl 7):32\u201339","journal-title":"CNS Spectr"},{"key":"2002_CR34","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0909392","volume":"362","author":"JJ McMurray","year":"2010","unstructured":"NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tam\u00e1s G, Tognoni G, Tuomilehto J, Villamil AS, Voz\u00e1r J, Califf RM (2010) Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 362:1477\u20131490","journal-title":"N Engl J Med"},{"key":"2002_CR35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","volume":"59","author":"JW Newcomer","year":"2002","unstructured":"Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G (2002) Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59:337\u2013345","journal-title":"Arch Gen Psychiatry"},{"key":"2002_CR36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/hr.2008.31","volume":"32","author":"T Ogihara","year":"2009","unstructured":"Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H, Japanese Society of Hypertension Committee (2009) The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 32:3\u2013107","journal-title":"Hypertens Res"},{"key":"2002_CR37","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","volume":"37","author":"GM Reaven","year":"1988","unstructured":"Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595\u20131607","journal-title":"Diabetes"},{"key":"2002_CR38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/01.ATV.11.1.80","volume":"11","author":"T R\u00f6nnemaa","year":"1991","unstructured":"R\u00f6nnemaa T, Laakso M, Py\u00f6r\u00e4l\u00e4 K, Kallio V, Puukka P (1991) High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects. Arterioscler Thromb 11:80\u201390","journal-title":"Arterioscler Thromb"},{"key":"2002_CR39","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1176\/appi.ajp.160.2.284","volume":"160","author":"MC Ryan","year":"2003","unstructured":"Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284\u2013289","journal-title":"Am J Psychiatry"},{"key":"2002_CR40","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.CIR.0000127955.36250.65","volume":"109","author":"M Schupp","year":"2004","unstructured":"Schupp M, Janke J, Clasen R, Unger T, Kintscher U (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109:2054\u20132057","journal-title":"Circulation"},{"key":"2002_CR41","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/01.HYP.0000125142.41703.64","volume":"43","author":"T Shiuchi","year":"2004","unstructured":"Shiuchi T, Iwai M, Li HS, Wu L, Min LJ, Li JM, Okumura M, Cui TX, Horiuchi M (2004) Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43:1003\u20131010","journal-title":"Hypertension"},{"key":"2002_CR42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.diabres.2004.11.001","volume":"69","author":"K Shiwaku","year":"2005","unstructured":"Shiwaku K, Anuurad E, Enkhmaa B, Nogi A, Kitajima K, Yamasaki M, Yoneyama T, Oyunsuren T, Yamane Y (2005) Predictive values of anthropometric measurements for multiple metabolic disorders in Asian populations. Diabetes Res Clin Pract 69:52\u201362","journal-title":"Diabetes Res Clin Pract"},{"key":"2002_CR43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/147323000002800401","volume":"28","author":"J Stangier","year":"2000","unstructured":"Stangier J, Su CA, Roth W (2000) Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 28:149\u2013167","journal-title":"J Int Med Res"},{"key":"2002_CR44","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(09)60619-X","volume":"373","author":"AG Tab\u00e1k","year":"2009","unstructured":"Tab\u00e1k AG, Jokela M, Akbaraly TN, Brunner EJ, Kivim\u00e4ki M, Witte DR (2009) Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373:2215\u20132221","journal-title":"Lancet"},{"key":"2002_CR45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/147323000203000103","volume":"30","author":"C Top","year":"2002","unstructured":"Top C, Cing\u00f6zbay BY, Terekeci H, K\u00fc\u00e7\u00fckardali Y, Onde ME, Danaci M (2002) The effects of valsartan on insulin sensitivity in patients with primary hypertension. J Int Med Res 30:15\u201320","journal-title":"J Int Med Res"},{"key":"2002_CR46","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","volume":"106","author":"G Viberti","year":"2002","unstructured":"Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106:672\u2013678","journal-title":"Circulation"},{"key":"2002_CR47","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.clinbiochem.2007.05.009","volume":"40","author":"M Vogeser","year":"2007","unstructured":"Vogeser M, K\u00f6nig D, Frey I, Predel HG, Parhofer KG, Berg A (2007) Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons. Clin Biochem 40:964\u2013968","journal-title":"Clin Biochem"},{"key":"2002_CR48","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.pnpbp.2007.08.022","volume":"32","author":"H Yamashita","year":"2008","unstructured":"Yamashita H, Yoda H, Maruki T, Toyoshima R (2008) Telmisartan, an angiotensin II type-1 receptor blocker, improved insulin resistance in a schizophrenic patient treated with olanzapine: a case report. Prog Neuropsychopharmacol Biol Psychiatry 32:308\u2013310","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2002_CR49","doi-asserted-by":"crossref","first-page":"41245","DOI":"10.1074\/jbc.M103241200","volume":"276","author":"T Yamauchi","year":"2001","unstructured":"Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Miki H, Tsuchida A, Akanuma Y, Nagai R, Kimura S, Kadowaki T (2001) The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276:41245\u201341254","journal-title":"J Biol Chem"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-010-2002-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-010-2002-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-010-2002-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T14:04:00Z","timestamp":1740492240000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-010-2002-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,4]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["2002"],"URL":"https:\/\/doi.org\/10.1007\/s00213-010-2002-9","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,4]]}}}